Global Melanoma Cancer Market Hits $10.5 billion in 2025 with 10.1% CAGR

Global melanoma cancer market was valued at $10.5 billion in 2025 and is growing at a CAGR of 10.1% during the forecast period (2026-2035). Regulatory support, including accelerated approval pathways and priority review mechanisms for advanced oncology indications, plays a crucial role in promoting innovation and facilitating the timely market entry of novel melanoma therapies. These frameworks aim to address high unmet needs in patients with advanced or treatment-resistant disease, where conventional therapeutic options offer limited clinical benefit.

Browse the full report description of “Melanoma Cancer Market Size, Share & Trends Analysis By Diagnosis (Biopsy, Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), and Others (PET)), and by Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Radiation therapy) Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/melanoma-cancer-market

For instance, in July 2025, the FDA approved a new therapy for patients with late-stage melanoma, an aggressive skin cancer, previously treated with surgery, immunotherapy, and chemotherapy. This innovative treatment provides hope for patients when traditional options are exhausted. Melanoma, primarily caused by excessive sun exposure, will diagnose over 104,000 individuals this year, with more than 8,000 expected fatalities. The new therapy serves as a significant advancement in the fight against advanced-stage melanoma.

Key Innovators Driving Melanoma Cancer Transformation

The key players in the melanoma cancer market include Bristol-Myers Squibb Co., Hoffmann-La Roche AG, Merck & Co., Inc., Novartis AG, and Pfizer Inc., among others. These companies are driving innovation in digital health solutions such as telemedicine, electronic health records, remote patient monitoring, and AI-powered clinical tools, shaping the future of healthcare delivery globally.

• In July 2025, the FDA issued a Complete Response Letter (CRL) regarding the combination of RP1 (vusolimogene oderparepvec) and nivolumab (Opdivo) for advanced melanoma treatment in patients previously treated with an anti-PD-1 regimen. The agency determined that data from the phase 1/2 IGNYTE trial were insufficient to demonstrate efficacy, citing issues with patient population heterogeneity and trial design elements.
• In February 2024, the FDA approved Amtagvi (lifileucel), the first cellular therapy for adult patients with unresectable or metastatic melanoma. This skin cancer treatment targets patients whose condition has not responded to previous therapies such as PD-1 blocking antibodies or BRAF inhibitors. Melanoma, despite being about 1% of skin cancers, leads to a high number of cancer deaths and can metastasize if not treated early. Amtagvi is an autologous T cell immunotherapy, derived from the patient's own T cells, which are extracted from tumor tissue, manufactured, and infused back into the patient, marking a significant advancement in cancer treatment.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Diagnosis
  • By Therapy
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Bristol-Myers Squibb Co., Hoffmann-La Roche AG, Merck & Co., Inc., Novartis AG, Pfizer Inc., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Melanoma Cancer Market Report Segment

By Diagnosis

• Biopsy
• Computed Tomography (CT) Scan
• Magnetic Resonance Imaging (MRI)
• Other Diagnosis

By Therapy

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• Surgery

Global Melanoma Cancer Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/melanoma-cancer-market